Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $248.0 million.

  • Medifast's Liabilities and Shareholders Equity fell 1275.1% to $248.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year decrease of 906.46%. This contributed to the annual value of $248.0 million for FY2025, which is 1275.1% down from last year.
  • Per Medifast's latest filing, its Liabilities and Shareholders Equity stood at $248.0 million for Q4 2025, which was down 1275.1% from $268.2 million recorded in Q3 2025.
  • Medifast's Liabilities and Shareholders Equity's 5-year high stood at $421.4 million during Q1 2022, with a 5-year trough of $248.0 million in Q4 2025.
  • Over the past 5 years, Medifast's median Liabilities and Shareholders Equity value was $317.5 million (recorded in 2022), while the average stood at $318.6 million.
  • As far as peak fluctuations go, Medifast's Liabilities and Shareholders Equity surged by 6146.74% in 2021, and later crashed by 2368.79% in 2023.
  • Over the past 5 years, Medifast's Liabilities and Shareholders Equity (Quarter) stood at $398.3 million in 2021, then decreased by 20.61% to $316.2 million in 2022, then dropped by 1.99% to $309.9 million in 2023, then fell by 8.29% to $284.2 million in 2024, then decreased by 12.75% to $248.0 million in 2025.
  • Its last three reported values are $248.0 million in Q4 2025, $268.2 million for Q3 2025, and $269.3 million during Q2 2025.